Jiangsu Kanion Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 7.54%

Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) is 7.54% for the year ending December 31, 2023, a 17.96% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 6.39%, a 20.03% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 5.33%, a 23.95% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 4.30%, a -48.21% change year over year.
Jiangsu Kanion Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 8.30%, a 7.76% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shanghai Stock Exchange: 600557.SS

Jiangsu Kanion Pharmaceutical Co.,Ltd.

CEO	Mr. Yongchun Yang
IPO Date	Sept. 18, 2002
Location	China
Headquarters	No. 58 Kangyuan Road
Employees	5,443
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.

Key trends

Past 5 years